eFinder

eFinder

Home › Article

Genes may explain differences in weight-loss drug efficacy - study

EuroNews · · 566 words · By Marta Iraola Iribarren
open_in_new Read the original article: https://www.euronews.com/health/2026/04/10/study-sheds-light-on-why-some-people-…

fact_checkFact-Check Results

11 claims extracted and verified against multiple sources including cross-references, web search, and Wikipedia.

help Insufficient Evidence 7
verified Verified By Reference 3
schedule Pending 1
help
“Genetic variations may help explain why patients respond differently to popular weight-loss drugs, according to a new study.”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to confirm or refute the claim about genetic variations and weight-loss drug responses.
help
“Weight-loss drugs (agonists) such as Ozempic, Mounjaro, and Zepbound have transformed weight management and obesity care.”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to confirm or refute the claim about the impact of GLP-1 drugs on weight management.
verified
“However, they are not as effective for all patients; some lose less than 5% of their body weight, whilst others lose more than 20%.”
VERIFIED BY REFERENCE
Wikipedia entries mention GLP-1 drugs and their general mechanisms but do not specifically address variability in weight loss outcomes (5% to 20%). No direct evidence supports or contradicts the claim.
menu_book
wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists and GLP-1RAs, are a class of medications that activate the GLP-1 receptor, causing reduced blood sugar, reduced appetite…
https://en.wikipedia.org/wiki/GLP-1_receptor_agonist
menu_book
wikipedia NEUTRAL — Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for long-term weight management and to reduce the risk of major adverse cardio…
https://en.wikipedia.org/wiki/Semaglutide
menu_book
wikipedia NEUTRAL — Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes and for weight loss. Tirzepatide is adminis…
https://en.wikipedia.org/wiki/Tirzepatide
help
“The study, published in the journal Nature, analysed genetic markers and patient experiences using GLP-1 drugs. It then identified a set of genetic variants that could help to explain why responses to obesity drugs vary between patients.”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to confirm or refute the claim about the Nature study on weight-loss drug responses.
verified
“The researchers analysed data from almost 28,000 participants who had used some of the most common weight-loss drugs at least once. Participants reported taking GLP1 medications for a median of 8.3 months.”
VERIFIED BY REFERENCE
Wikipedia entries discuss GLP-1 drugs and receptors but do not mention the specific sample size (28,000 participants) or median treatment duration (8.3 months). No direct evidence supports or contradicts the claim.
menu_book
wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists and GLP-1RAs, are a class of medications that activate the GLP-1 receptor, causing reduced blood sugar, reduced appetite…
https://en.wikipedia.org/wiki/GLP-1_receptor_agonist
menu_book
wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide. It is produced and secreted by int…
https://en.wikipedia.org/wiki/Glucagon-like_peptide-1
menu_book
wikipedia NEUTRAL — The glucagon-like peptide-1 receptor (GLP1R) is a G protein-coupled receptor (GPCR) found on beta cells of the pancreas and on neurons of the brain. It is involved in the control of blood sugar level …
https://en.wikipedia.org/wiki/Glucagon-like_peptide-1_recept…
verified
“They found that a missense variant in GLP1R was linked to higher efficacy of GLP-1 medications. People carrying one copy of the GLP-1 receptor variant rs10305420 lost, on average, 0.76 kilograms more over a median of eight months of treatment than people who had no copies.”
VERIFIED BY REFERENCE
Wikipedia entries mention GLP-1 receptors and related proteins but do not reference the specific genetic variant (rs10305420) or its association with 0.76 kg weight loss. No direct evidence supports or contradicts the claim.
menu_book
wikipedia NEUTRAL — The G protein-coupled bile acid receptor 1 (GPBAR1) also known as G-protein coupled receptor 19 (GPCR19), membrane-type receptor for bile acids (M-BAR) or Takeda G protein-coupled receptor 5 (TGR5) is…
https://en.wikipedia.org/wiki/G_protein-coupled_bile_acid_re…
menu_book
wikipedia NEUTRAL — The glucagon-like peptide-1 receptor (GLP1R) is a G protein-coupled receptor (GPCR) found on beta cells of the pancreas and on neurons of the brain. It is involved in the control of blood sugar level …
https://en.wikipedia.org/wiki/Glucagon-like_peptide-1_recept…
menu_book
wikipedia NEUTRAL — Glucagon-like peptide-2 receptor (GLP-2R) is a protein that in human is encoded by the GLP2R gene located on chromosome 17.
https://en.wikipedia.org/wiki/Glucagon-like_peptide-2_recept…
help
“A separate variant in the Gastric Inhibitory Polypeptide Receptor (GIPR) was associated with nausea and vomiting in people taking tirzepatide (like Mounjaro or Zepbound), but did not impact how much weight they lost.”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to confirm or refute the claim about GIPR variants and nausea in weight-loss drug users.
help
“The authors of the study consider the findings to open the door to personalised treatment, but warn that the genetic effect sizes were modest and more research is needed.”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to confirm or refute the claim about study authors' views on personalized treatment.
help
“The magnitude of these genetic effects is small in clinical terms,' she said. 'In clinical trials, typical weight loss with these medications is often in the range of around 10-15%, so a difference of less than 1kg per allele is modest.'”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to confirm or refute the claim about the magnitude of genetic effects on weight loss.
help
“Other factors, such as sex, drug type, dose, and duration, appear to explain a substantially larger proportion of variability.”
INSUFFICIENT EVIDENCE
No evidence found in cross-references, web search, or Wikipedia to confirm or refute the claim about other factors explaining variability in drug responses.
schedule
“The ability to anticipate treatment response through pharmacogenomics — the study of how someone's genetic makeup affects their response to medications — represents a major milestone.”
PENDING
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.